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Ovarian cancera b s t r a c t
Aberrant epidermal growth factor receptor (EGFR) activation is associated with ovarian cancer pro-
gression. In this study, we report that the EGFR ligand amphiregulin (AREG) stimulates cell invasion
and down-regulates E-cadherin expression in two human ovarian cancer cell lines, SKOV3 and
OVCAR5. In addition, AREG increases the expression of transcriptional repressors of E-cadherin
including SNAIL, SLUG and ZEB1. siRNA targeting SNAIL or SLUG abolishes AREG-induced cell inva-
sion. Moreover, ERK1/2 and AKT pathways are involved in AREG-induced E-cadherin down-regula-
tion and cell invasion. Finally, we show that three EGFR ligands, AREG, epidermal growth factor
(EGF) and transforming growth factor-a (TGF-a), exhibit comparable effects in down-regulating E-
cadherin and promoting cell invasion. This study demonstrates that AREG induces ovarian cancer
cell invasion by down-regulating E-cadherin expression.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ovarian cancer is a common cancer and represents the most
lethal gynecological cancer. The high mortality rate is caused by
a lack of reliable screening tests and obvious symptoms, which fre-
quently results in diagnosis at advanced disease stages when per-
itoneal metastasis is already present [1]. Impairment of the
epidermal growth factor receptor (EGFR) system is known to play
a role in ovarian cancer by directly enhancing the invasiveness and
metastatic potential of cancer cells [2–8]. EGFR ampliﬁcation,
mutation and protein overexpression have been reported in ovar-
ian cancer [9–12]. Alternatively, aberrant EGFR activity may be a
result of overproduction of EGFR ligands.
Most studies examining the roles of speciﬁc EGFR ligands in
ovarian cancer are biased towards the growth- and invasion-pro-
moting roles of EGF and transforming growth factor-a (TGF-a)
[13]. However, elucidation of the role played by another EGFR-
exclusive ligand, amphiregulin (AREG), is also necessary because
these ligands are distinct in many aspects and may mediate diversephysiological outcomes. In addition to the differences in its binding
afﬁnity for the EGFR [14], AREG is structurally unique because it
contains a heparin-binding domain not present in EGF and
TGF-a. This domain mediates the binding of AREG to heparan sul-
fate proteoglycans, resulting in the accumulation of higher concen-
trations of AREG at the cell surface, which can activate EGFR
[15,16]. Moreover, AREG impairs EGFR degradation [17,18], leading
to sustained EGFR levels and activity. More importantly, these pep-
tides are functionally non-redundant. For example, treatment with
AREG, but not TGF-a, leads to actin reorganization and the acquisi-
tion of a motile morphology in MDCK cells [19].
AREG levels are higher than TGF-a and EGF levels in ovarian
cancer tissues and cell lines [20,21]. Similarly, the concentration
of AREG in the peritoneal ﬂuid of ovarian cancer patients at differ-
ent stages of the disease ranges between 203–225 pg/ml and is sig-
niﬁcantly higher than the concentration of TGF-a (2.01–8.33 pg/
ml) [22]. These data strongly suggest that AREG is a dominant
autocrine/paracrine ligand activating EGFR in ovarian cancer cells.
To date, studies of the physiological role of AREG in ovarian can-
cer have been restricted to its role in cell proliferation [20,23]. In
ovarian cancer cells and normal ovarian surface epithelial cells,
AREG induces a biphasic regulation of proliferation [23]. The cur-
rent study demonstrates a pro-invasive potential of AREG and elu-
cidates the underlying molecular mechanisms. Our results
demonstrated a signiﬁcant effect of AREG in down-regulating E-
cadherin and promoting the cell invasion. AREG activates the
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cadherin transcriptional repressor SLUG and the subsequent loss of
E-cadherin.
2. Materials and methods
2.1. Cell culture and reagents
The SKOV3 ovarian cancer cell line was obtained from the
American Type Culture Collection (Manassas, VA). The OVCAR5
ovarian cancer cell line was kindly provided by Dr. T.C. Hamilton
(Fox Chase Cancer Center, Philadelphia, PA). The cell lines were
cultured in MCDB 105/M199 (1:1) (Sigma–Aldrich, Oakville, ON)
supplemented with 5% heat-inactivated fetal bovine serum (FBS,
Hyclone Laboratories, Logan, UT), 100 IU/ml penicillin and
100 lg/ml streptomycin. The cells were cultured at 37 C under
5% CO2. U0126 was purchased from Calbiochem (San Diego,
CA). Human epidermal growth factor (EGF) and LY294002 were
obtained from Sigma. Recombinant human amphiregulin and
TGF-a were obtained from R&D systems (Minneapolis, MN).
Anti-E-cadherin and anti-N-cadherin antibodies were obtained
from BD Biosciences (Mississauga, ON). Anti-SNAIL, anti-SLUG,
anti-ZEB1, anti-phospho-AKT (Ser473), anti-total AKT, anti-phos-
pho-ERK1/2 (Thr202/Tyr204) and anti-ERK1/2 antibodies were
purchased from Cell Signaling Technology (Danvers, MA). Anti-
actin antibody was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA).
2.2. Transfection
The empty pcDNA3.1-EGFP vector was obtained from Invitro-
gen (Burlington, ON). A human E-cadherin-containing pcDNA3.1-
EGFP vector (plasmid 28009) was purchased from Addgene (Cam-
bridge MA). Plasmids were transfected using Lipofectamine 2000
(Invitrogen). ON-TARGETplus SMARTpool siRNA for SNAIL, SLUG,
ZEB1, AREG and non-targeting siRNA (Dharmacon, Lafayette, CO)
were transfected using Lipofectamine RNAiMAX (Invitrogen).
2.3. Real-time quantitative PCR (RT-qPCR)
Total RNA was extracted from cells using TRIzol Reagent (Invit-
rogen) and used in ﬁrst-strand DNA (cDNA) synthesis with the
Invitrogen Super-Script ﬁrst strand synthesis system for RT-qPCR
according to the manufacturer’s protocol. RT-qPCR was performed
using an Applied Biosystems 7300 Real-Time PCR System (ABI,
Hercules, CA) equipped with a 96-well optical reaction plate. The
ampliﬁcations of SNAIL, SLUG, ZEB1 and the internal control GAP-
DH were performed as follows: a 3 min hot start at 95 C followed
by 40 cycles of denaturation at 95 C for 15 s and ampliﬁcation at
60 C for 1 min. PCR reactions were performed in duplicate with
the following PCR primers: E-cadherin, forward 50-GGG TGA CTA
CAA AAT CAA TC-30 and reverse 50-AAA GAG CCC TTA CTG CCC
CC-30; SNAIL, forward 50-CCC CAA TCG GAA GCC TAA CT-30 and
reverse 50-GCT GGA AGG TAA ACT CTG GAT TAG A-30; SLUG, for-
ward 50-TTC GGA CCC ACA CAT TAC CT-30 and reverse 50-GCA
GTG AGG GCA AGA AAA AG-30; ZEB1, forward 50-GCA CCT GAA
GAG GAC CAG AG-30 and reverse 50-TGC ATC TGG TGT TCC ATT
TT-30 and GAPDH, forward 50-GAG TCA ACG GAT TTG GTC GT-30
and reverse 50-GAC AAG CTT CCC GTT CTC AG-30. The mRNA levels
of AREG were examined by TaqMan gene expression assays
(Applied Biosystems, Burlington, ON). All RT-qPCR results repre-
sent the mean from at least three independent experiments. Rela-
tive quantiﬁcation of mRNA levels was performed by the
comparative Ct method using GAPDH as the reference gene and
the formula 2DDCt.2.4. Western blot analysis
Equal amounts of total cell lysate were resolved on 10% SDS–
PAGE gels and electrotransferred to a PVDF membrane. After block-
ing for 1 h with 5% non-fat dry milk in TBS-T buffer (20 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20), the blots were probed
for overnight at 4 C with the primary antibodies. The blots were
then incubated with a peroxidase-conjugated secondary antibody
(Bio-Rad) for 1 h followed by detection with ECL chemilumines-
cence reagent (Amersham, Arlington Heights, IL) and exposure on
X-ray ﬁlms.
2.5. Immunoﬂuorescence
For immunoﬂuorescence, cells grown on glass coverslips were
ﬁxed in 4% paraformaldehyde. The cells were incubated with an
anti-human E-cadherin antibody (mousemonoclonal, BD Transduc-
tion Laboratories) at 1:100 dilution at room temperature for 1 h. The
anti-E-cadherin antibody was replaced with mouse IgG in negative
controls. Cells were washed thrice with PBS and incubated with
Alexa Fluor 594-conjugated goat anti-mouse antibodies (Life Tech-
nologies, Burlington, ON) at room temperature for 1 h. Cells were
mounted and stained with 4,6-diamidino-2-phenylindole (DAPI)
and viewed using a ﬂuorescence microscope (Leica, Bensheim,
Germany).
2.6. Invasion assay
To assess invasion, 24-well transwell ﬁlters with 8-lm pores
coated with 1 mg/ml Matrigel (50 ll/well; BD Sciences) were used.
Ovarian cancer cells were trypsinised, re-suspended in 0.1% FBS
medium and seeded in triplicate in the upper chamber. Medium
containing 1% FBSwas added to the lowerwells. The chamberswere
incubated for 24 h at 37 C in a 5%CO2 atmosphere. The cells that did
not penetrate the ﬁlter were wiped off. The invading cells on the
lower surface of theﬁlterwere ﬁxedwith ice-coldmethanol, stained
with Hoechst 33258 and counted through epiﬂuorescence micros-
copy with Northern Eclipse 6.0 software (Empix Imaging, Mississa-
uga, ON). Triplicate inserts were used for each individual
experiment, and the results are presented as the pecentage changes
compared to the control.
2.7. Statistical analysis
The results were presented as the mean ± S.E.M. of at least three
independent experiments. Statistical evaluation was performed
using a t-test for paired data. Multiple comparisons were ﬁrst ana-
lyzed using one-way ANOVA, followed by Tukey’smultiple compar-
ison tests using PRISMsoftware. A signiﬁcant differencewas deﬁned
as P < 0.05.
3. Results
3.1. AREG induces human ovarian cancer cell invasion
As a ﬁrst step to investigate the role of AREG in ovarian cancer
progression, we tested the effect of AREG on the invasion of ovar-
ian cancer cells using a Matrigel-coated transwell assay. It has been
shown that the concentration of AREG in the human follicular ﬂuid
can reach 100 ng/ml [24]. Therefore, two human ovarian cancer
cell lines, SKOV3 and OVCAR5, were incubated with 1, 10 and
100 ng/ml of AREG and allowed to invade across the transwell
for 24 h. As shown in Fig. 1, treatment with 1 ng/ml AREG did
not induce cell invasion, whereas treatment with 10 and 100 ng/
ml AREG exhibited comparable stimulatory effects on the invasive-
Fig. 1. AREG induces ovarian cancer cell invasion. SKOV3 (A) and OVCAR5 (B) cell were treated with 0 (Ctrl), 1, 10 and 100 ng/ml AREG and seeded onto Matrigel-coated
transwell inserts and cultured for 24 h. Non-invading cells were wiped from the upper side of the ﬁlter, and the nuclei of invading cells were stained with Hoechst 33258. The
top panel shows representative photos of the invasion assay. The bottom panel shows a summary of the quantitative results, which are expressed as the mean ± S.E.M. of at
least three independent experiments. Values without a common letter were signiﬁcantly different (P < 0.05).
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AREG was used in the ensuing experiments.
3.2. AREG down-regulates E-cadherin and restoration of E-cadherin
blocks AREG-induced ovarian cancer cell invasion
Ovarian cancer cell invasion is thought to be a consequence of
loss of the adhesion molecule E-cadherin [1], prompting us to
investigate the changes in E-cadherin levels after AREG treatment.
In agreement with the effect on cell invasion, we found that AREG
treatment down-regulated E-cadherin protein levels in SKOV3 cells
in a dose-dependent manner. Interestingly, AREG did not affect the
protein levels of N-cadherin (Fig. 2A). Through immunoﬂuores-
cence staining of E-cadherin, we observed that SKOV3 cells
adopted a cluster phenotype with few intercellular spaces. After
treatment with AREG for 24 h, the cells became less adherent,
and most of them were well separated (Fig. 2B). In addition, AREG
treatment also down-regulated E-cadherin in another ovarian can-
cer cell line, OVCAR5 (Fig. 2C). To establish a deﬁnite causal link
between E-cadherin loss and increased cell invasiveness, we trans-
fected SKOV3 cells with a human E-cadherin expression plasmid
for 48 h and treated with AREG for 24 h. As shown in Fig. 2D, E-cad-
herin overexpression not only suppressed the basal invasiveness
but also reversed cell invasion induced by AREG. Similar to the
untransfected cells, AREG scattered the clusters of control vector-
transfected cells. Importantly, E-cadherin overexpression abol-
ished the scattering effect of AREG, with most of the cells remain-
ing adherent, and the cluster phenotype was maintained (Fig. 2E).
3.3. The ERK1/2 and PI3K/AKT pathways mediate the effects of AREG-
induced down-regulation of E-cadherin and cell invasion
The ERK1/2 and PI3K/AKT pathways are dysregulated and
implicated in ovarian cancer progression. In addition, we have pre-
vious reported that these pathways mediate growth factor-induced
down-regulation of E-cadherin expression and cell invasion in
human ovarian cancer cells [25–27]. Therefore, the effects of AREG
on the activation of the ERK1/2 and PI3K/AKT pathways wereexamined. Our results demonstrated that treatment with AREG
strongly induced the phosphorylation of ERK1/2 and AKT in SKOV3
cells (Fig. 3A). In addition, AREG-induced phosphorylation levels of
ERK1/2 and AKT were speciﬁcally abolished by treatment with the
MEK inhibitor U0126 and the PI3K inhibitor LY294002, respec-
tively (Fig. 3A). Inhibition of both the ERK1/2 and PI3K/AKT path-
ways attenuated AREG-induced down-regulation of E-cadherin
(Fig. 3B). Importantly, U0126 and LY294002 abolished the basal
as well as AREG-induced cell invasion (Fig. 3C).
3.4. AREG induces SLUG through the ERK1/2 and PI3K/AKT pathways
To examine the involvement of transcriptional repressors in E-
cadherin down-regulation by AREG, we investigated the effects of
AREG on the expressions of SNAIL, SLUG and ZEB1. In both time-
and dose-course experiments, AREG strongly elevated the mRNA
levels of SLUG and, to lesser extents, SNAIL and ZEB1 (Fig. 4A). At
transcriptional level, treatment with AREG down-regulated E-cad-
herin mRNA levels in a time-dependent manner (Fig. 4B). Western
blot analysis also revealed positive effects of AREG on SNAIL and
ZEB1 protein levels as well as the robust stimulatory effect on
SLUG protein (Fig. 4C). Inhibition of both the ERK1/2 and PI3K/
AKT pathways attenuated AREG-induced SLUG mRNA levels
(Fig. 4D). Accordingly, the AREG-induced SLUG protein levels were
attenuated by treatment with U0126 and LY294002 (Fig. 4E).
3.5. Knockdown of SLUG abolishes AREG-induced cell invasion
Next, we asked whether the transcriptional repressors of E-cad-
herin are important for AREG-induced cell invasion. SKOV3 cells
were transfected with siRNAs targeting SNAIL, SLUG and ZEB1. As
shown in Fig. 5A, SNAIL, SLUG and ZEB1 siRNA speciﬁcally knocked
down the expression levels induced by AREG. Invasion assays indi-
cated that knockdown of SNAIL attenuated AREG-induced cell
invasion but did not affect the basal cell invasiveness. Surprisingly,
knockdown of ZEB1 did not affect the basal or AREG-induced cell
invasion. Interestingly, knockdown of SLUG dramatically inhibited
the basal as well as AREG-induced cell invasion (Fig. 5B).
Fig. 2. AREG down-regulates E-cadherin and restoration of E-cadherin blocks AREG-induced ovarian cancer cell invasion. (A) SKOV3 cells were treated with 0 (Ctrl), 1, 10 and
100 ng/ml AREG for 24 h. The protein levels of E-cadherin and N-cadherin were examined by Western blotting. (B) SKOV3 cells were treated with 0 (Ctrl), 10 and 100 ng/ml
AREG for 24 h. IgG was used as negative control. The expression and localization of E-cadherin were examined by immunoﬂuorescent staining. (C) OVCAR5 cells were treated
with 0 (Ctrl), 1, 10 and 100 ng/ml AREG for 24 h. The protein levels of E-cadherin were examined by Western blotting. (D) SKOV3 cells were transfected with EGFP vector
(Vector Ctrl) or human E-cadherin expression vector (E-cad-EGFP) for 48 h and the protein levels of E-cadherin were examined by Western blotting. After transfection, cell
were treated with 10 ng/ml AREG and seeded onto Matrigel-coated transwell inserts and cultured for 24 h. Non-invading cells were wiped from the upper side of the ﬁlter,
and the nuclei of invading cells were stained with Hoechst 33258. (E) SKOV3 cells were transfected with EGFP vector (Vector Ctrl) or human E-cadherin expression vector (E-
cad-EGFP) for 48 h and treated with 10 ng/ml AREG for 24 h. The expression and localization of E-cadherin were examined by immunoﬂuorescent staining. The results are
expressed as the means ± S.E.M. of at least three independent experiments. Values without a common letter were signiﬁcantly different (P < 0.05).
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Fig. 3. The ERK1/2 and PI3K/AKT pathways mediate the effects of AREG-induced down-regulation of E-cadherin and cell invasion. (A) SKOV3 cells were pretreated for 30 min
with U0126 (10 lM) or LY294002 (10 lM) and then treated with 10 ng/ml AREG for 30 min. The levels of phosphorylated ERK1/2 and AKT were analyzed byWestern blotting.
(B) SKOV3 cells were pretreated for 30 min with U0126 (10 lM) or LY294002 (10 lM) and then treated with 10 ng/ml AREG for 24 h. The protein levels of E-cadherin were
analyzed by Western blotting. (C) SKOV3 cells were pretreated for 30 min with U0126 (10 lM) or LY294002 (10 lM). After pre-treatment, cells were treated with 10 ng/ml
AREG and seeded onto Matrigel-coated transwell inserts and cultured for 24 h. Non-invading cells were wiped from the upper side of the ﬁlter, and the nuclei of invading cells
were stained with Hoechst 33258. The results are expressed as the means ± S.E.M. of at least three independent experiments. Values without a common letter were
signiﬁcantly different (P < 0.05).
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cell invasion
AREG has been shown to act as autocrine factor to regulate
human breast, liver and ovarian cancer progression [28–30]. To
examine whether inhibition of AREG affect the expression levels
of E-cadherin and ovarian cancer cell invasion, SKOV3 cells were
transfected with AREG siRNA to knockdown endogenous AREG
expression. As shown in Fig. 6A, TaqMan gene expression assays
showed that AREG siRNA signiﬁcant down-regulated endogenous
AREG mRNA levels. In addition, knockdown of AREG increased E-
cadherin protein levels but did not affect the expression levels of
N-cadherin (Fig. 6B). Moreover, the cell invasiveness was
decreased after knockdown of AREG (Fig. 6C). These results indi-
cated that AREG acted as autocrine factor to induce human ovarian
cancer invasion by down-regulating E-cadherin expression.
3.7. AREG, EGF and TGF-a exhibit comparable effects on the ERK1/2
and PI3K/AKT pathway activation, E-cadherin down-regulation and
cell invasion
As a ﬁrst step to elucidate the relative importance of the three
EGFR ligands in ovarian cancer cell invasion, we compared their
effects on the ERK1/2/AKT-SLUG-E-cadherin axis. When SKOV3
cells were treated with AREG, EGF or TGF-a (100 ng/ml) for 5, 30
and 180 min, the levels of phosphorylated ERK1/2 and AKT were
comparable (Fig. 7A). We also compared the effects of AREG, EGF
and TGF-a on SLUG protein levels. As shown in Fig. 7B, all the three
ligands caused a robust induction of SLUG protein, and EGF
induced a higher level of SLUG protein than did AREG. Neverthe-
less, the extent of E-cadherin protein down-regulation induced
by the three ligands was similar (Fig. 7C). Immunoﬂuorescent
staining of E-cadherin revealed that, in response to all the three
ligands, SKOV3 cells became less adherent, and most of them were
well separated (Fig. 7D). Moreover, there was no signiﬁcant differ-
ence between the extent of cell invasion induced by the three
ligands (Fig. 7E).4. Discussion
This study demonstrates a pro-invasive role of AREG in ovarian
cancer cells. In other malignancies, most of the reported invasion-
promoting effects of AREG are associated with protease-mediated
extracellular matrix (ECM) degradation. For example, urokinase-
type plasminogen activator inhibitor-1 is responsible for AREG-
induced invasion of breast cancer cells [31]. Moreover, the levels
and activities of matrix metalloproteinases (MMP) are up-regu-
lated by AREG to mediate the invasion of different cancer cells
[32–35]. AREG also regulates the levels of extracellular matrix
metalloproteinase inducers in transformed breast epithelial cells
[34]. In addition, integrin, which couples the ECM to the intracellu-
lar cytoskeleton and whose level and activation are altered during
colon cancer cell invasion, is induced by AREG [36]. Here, we report
that AREG stimulates ovarian cancer cell invasion by down-regu-
lating the cell surface adhesion molecule E-cadherin. Similarly,
AREG has been reported to reduce E-cadherin levels and adherence
in keratinocytes [37]. Moreover, AREG promotes a reduction in
membrane-localized E-cadherin and a motile morphology in
MDCK cells [19], suggesting that E-cadherin is a common mediator
of AREG-stimulated cell motility.
Loss of adhesion junctions and disruption of cell–cell contact
are prerequisites for tumor cell exfoliation and metastasis [38].
Reduced E-cadherin levels have been associated with ovarian can-
cer intra-peritoneal and lymph node metastasis [39,40]. E-cadherin
expression is transcriptionally silenced in ovarian cancer, either
through epigenetic promoter hypermethylation [40,41] or as a
result of the induction of the transcriptional repressors SNAIL
and SLUG [42,43]. In our study, AREG elevated the levels of SNAIL,
SLUG and ZEB1, although SLUG expression responded most drasti-
cally. Silencing SLUG exhibited the most prominent effects in
attenuating AREG-induced as well as basal cell invasion, support-
ing the essential role in ovarian cancer cell invasion played by
SLUG. We have demonstrated the importance of SLUG in mediating
E-cadherin repression and an increase in ovarian cancer cell motil-
ity in response to estradiol [43] and ﬁbroblast growth factor-2 [25].
Fig. 4. AREG induces SLUG through the ERK1/2 and PI3K/AKT pathways. (A) SKOV3 cells were treated with 10 ng/ml AREG for different periods (top panel) or treated with 0
(Ctrl), 1, 10 and 100 ng/ml AREG for 3 h (bottom panel). The mRNA levels of SNAIL, SLUG and ZEB1 were analyzed by RT-qPCR. (B) SKOV3 cells were treated with 10 ng/ml
AREG for different periods and the mRNA levels of E-cadherin were analyzed at by RT-qPCR. (C) SKOV3 cells were treated with 10 ng/ml AREG for 3 h and the protein levels of
SNAIL, SLUG and ZEB1 were analyzed by Western blotting. (D and E) SKOV3 cells were pretreated for 30 min with U0126 (10 lM) or LY294002 (10 lM). After pre-treatment,
cells were treated with 10 ng/ml AREG for 3 h and the mRNA (D) and protein (E) levels of SLUG were analyzed by RT-qPCR and Western blotting, respectively. The results are
expressed as the means ± S.E.M. of at least three independent experiments. Values without a common letter were signiﬁcantly different (P < 0.05).
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HER2 [44]. In human gliomas, SLUG overexpression correlates with
histologic grade and invasive phenotype [45]. SLUG mRNA expres-sion correlates positively with lung cancer cell line invasiveness
[46]. In additional to E-cadherin, chemokines and their receptors
[47] and MMP [46,48] have been shown to mediate SLUG actions
Fig. 6. Knockdown of AREG increases E-cadherin expression and inhibits cell invasion. (A
for 24 h. The mRNA levels of AREG were analyzed by TaqMan probe-based RT-qPCR. (B) S
48 h. The protein levels of E-cadherin and N-cadherin were analyzed by Western blott
(siAREG) for 48 h and then seeded onto Matrigel-coated transwell inserts for culturing an
nuclei of invading cells were stained with Hoechst 33258. The results are expressed a
common letter were signiﬁcantly different (P < 0.05).
Fig. 5. Knockdown of SLUG abolishes AREG-induced cell invasion. (A) SKOV3 cells
were transfected with a control siRNA (siCtrl), SNAIL siRNA (siSNAIL), SLUG siRNA
(siSLUG) or ZEB1 siRNA (siZEB1) for 48 h. After transfection, cells were treated with
10 ng/ml AREG for 3 h and the protein levels of SNAIL, SLUG and ZEB1 were
analyzed by Western blotting. (B) SKOV3 cells were transfected with a control
siRNA (siCtrl), SNAIL siRNA (siSNAIL), SLUG siRNA (siSLUG) or ZEB1 siRNA (siZEB1)
for 48 h. After transfection, cells were treated with 10 ng/ml AREG and seeded onto
Matrigel-coated transwell inserts and cultured for 24 h. Non-invading cells were
wiped from the upper side of the ﬁlter, and the nuclei of invading cells were stained
with Hoechst 33258. The results are expressed as the means ± S.E.M. of at least
three independent experiments. Values without a common letter were signiﬁcantly
different (P < 0.05).
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that SLUG is an important mediator in the regulation of cell migra-
tion and invasion.
Although acting through the same receptor, AREG, EGF and TGF-
a may elicit different biological responses. AREG promotes E-cad-
herin redistribution and epithelial–mesenchymal transition in
MDCK cells, neither of which occur following treatment with
TGF-a [19]. Likewise, stimulation with AREG, but not EGF,
increases mammary epithelial cell motility [49]. Therefore, it is
plausible and interesting to investigate the similarities and differ-
ences among the EGFR ligands. Our results revealed that the mag-
nitudes and proﬁles of AREG-, EGF- or TGF-a-induced activation of
ERK1/2 and AKT were similar. Accordingly, we also demonstrated
that the three ligands exhibited comparable effects on the down-
regulation of E-cadherin and cell invasion. The ERK1/2 and PI3K/
AKT pathways are well-established mediators of EGFR. Here, we
demonstrated the rapid and robust activation of these pathways
after AREG treatment. We also provided substantial evidence
strengthening the involvement of these pathways in AREG/EGFR-
induced cell invasion. Pharmacological inhibitions of the pathways
attenuated the effects of AREG-induced up-regulation of SLUG,
down-regulation of E-cadherin and cell invasion. Taken together,
the three EGFR ligands have comparable effects on the ERK1/2/
AKT-E-cadherin pathway and cell invasion; their relative impor-
tance might be determined by their abundance.
It has been shown that AREG stimulates cancer cell invasion by
increasing MMPs expression levels and activities [32–35]. In addi-
tion, ERK1/2 and PI3K/AKT signaling pathways are involved in reg-
ulation of MMPs expression in human ovarian cancer [6].
Therefore, inhibition of MMPs expression or activity by U0126 or
LY294002 may explain why these two pharmacological inhibitors
only partially attenuated AREG-induced SLUG expression but) SKOV3 cells were transfected with a control siRNA (siCtrl) or AREG siRNA (siAREG)
KOV3 cells were transfected with a control siRNA (siCtrl) or AREG siRNA (siAREG) for
ing. (C) SKOV3 cells were transfected with a control siRNA (siCtrl) or AREG siRNA
other 24 h. Non-invading cells were wiped from the upper side of the ﬁlter, and the
s the means ± S.E.M. of at least three independent experiments. Values without a
Fig. 7. AREG, EGF and TGF-a exhibit comparable effects on the ERK1/2 and PI3K/AKT pathways activation, E-cadherin down-regulation and cell invasion. (A) SKOV3 cells
were treated with 100 ng/ml AREG (A), EGF (E) or TGF-a (T) for different periods. The levels of phosphorylated ERK1/2 and AKT were analyzed by Western blotting. (B) SKOV3
cells were treated with 100 ng/ml AREG (A), EGF (E) or TGF-a (T) for 3 h and the protein levels of SLUG were analyzed by Western blotting. (C) SKOV3 cells were treated with
100 ng/ml AREG (A), EGF (E) or TGF-a (T) for 24 h and the protein levels of E-cadherin were analyzed by Western blotting. (D) SKOV3 cells were treated with 100 ng/ml AREG
(A), EGF (E) or TGF-a (T) for 24 h and the expression and localization of E-cadherin were examined by immunoﬂuorescent staining. (E) SKOV3 cell were treated with 100 ng/
ml AREG (A), EGF (E) or TGF-a and seeded onto Matrigel-coated transwell inserts and cultured for 24 h. Non-invading cells were wiped from the upper side of the ﬁlter, and
the nuclei of invading cells were stained with Hoechst 33258. The top panel shows representative photos of the invasion assay. The bottom panel shows a summary of the
quantitative results. The results are expressed as the means ± S.E.M. of at least three independent experiments. Values without a common letter were signiﬁcantly different
(P < 0.05).
W.-K. So et al. / FEBS Letters 588 (2014) 3998–4007 4005totally blocked the AREG-induced cell invasion. Our results also
showed that treatment with U0126 or LY294002 decreased basal
SLUG mRNA levels although not statistical different was observed.
However, this effect would result in slightly increased basal levels
of E-cadherin after U0126 or LY294002 treatment.
Although our data did not support a unique role for AREG, the
relatively higher levels of AREG compared with the levels of TGF-
a and EGF in ovarian cancer tissues and patients [20–22] suggest
that AREG is the dominant ligand activating EGFR in ovarian cancer
cells. A recent study shows that a self-reinforcing loop of AREG in
ovarian cancer cells can contribute to cell invasiveness [30]. Fur-
thermore, when the invasion-promoting effect of AREG is consid-
ered in the context of ovarian cancer pathogenesis; AREG mayact as an autocrine factor that promotes tumor progression. Indeed,
our results showed that knockdown of AREG not only increased E-
cadherin expression but also inhibited ovarian cancer cell invasion
which further conﬁrmed the autocrine role of AREG in regulation of
ovarian cancer progression. AREG is a direct transcriptional target
of oncogenes and tumor-suppressor genes, including RAS [50],
RAF [51], BRCA1 [52] and hypoxia inducible factor-2a (HIF-2a)
[53]. Importantly, E-cadherin levels are suppressed by SLUG in
oncogenic RAS-transformed epithelial cells [54]. Therefore, AREG
could be anticipated to mediate the effect of RAS on the trans-
formed phenotype. In the same vein, AREG is up-regulated by
Wnt/b-catenin signaling and has been proposed to confer the che-
moresistance caused by Wnt signaling [55]. Furthermore, AREG
4006 W.-K. So et al. / FEBS Letters 588 (2014) 3998–4007has been shown to be up-regulated by luteinizing hormone (LH) in
mouse and human granulosa cells [56,57]. These ﬁndings not only
suggest a high local concentration of AREG in the ovaries but also
suggest a causal link between LH, AREG and ovarian cancer. We
have previously demonstrated that LH stimulates ovarian cancer
cell migration and invasion [58,59]. However, whether LH can also
up-regulate AREG in ovarian cancer cells remains unknown. There-
fore, future studies will be needed to investigate the directly
involvement of AREG in LH-induced ovarian cancer invasion.
In summary, our study demonstrates that AREG induces human
ovarian cancer cell invasion by down-regulating E-cadherin
expression. In addition, the ERK1/2 and PI3K/AKT pathways are
involved in AREG-induced down-regulation of E-cadherin expres-
sion and cell invasion. Our results also indicate that SLUG is a
major transcriptional repressor that mediates AREG-induced
down-regulation of E-cadherin and cell invasion Moreover, three
EGFR ligands, AREG, EGF and TGF-a, exhibit similar effects on the
induction of SLUG, the down-regulation of E-cadherin and the
induction of cell invasion.
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